Technical Analysis for PEPG - PepGen Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 6.48 | -2.11% | -0.14 |
PEPG closed down 2.11 percent on Friday, November 1, 2024, on 41 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | -2.11% | |
| Lower Bollinger Band Walk | Weakness | -2.11% |
| Alert | Time |
|---|---|
| Down 3% | about 19 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
| Down 2 % | about 19 hours ago |
| Down 1% | about 19 hours ago |
| Possible NR7 | about 19 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/08/2024
PepGen, Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Deliver Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Molecular Biology Cell Biology Peptides Oligonucleotide Nucleic Acids
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Molecular Biology Cell Biology Peptides Oligonucleotide Nucleic Acids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.298 |
| 52 Week Low | 3.725 |
| Average Volume | 83,353 |
| 200-Day Moving Average | 12.49 |
| 50-Day Moving Average | 8.82 |
| 20-Day Moving Average | 8.38 |
| 10-Day Moving Average | 7.71 |
| Average True Range | 0.53 |
| RSI (14) | 20.63 |
| ADX | 31.06 |
| +DI | 7.60 |
| -DI | 34.41 |
| Chandelier Exit (Long, 3 ATRs) | 8.33 |
| Chandelier Exit (Short, 3 ATRs) | 7.96 |
| Upper Bollinger Bands | 10.21 |
| Lower Bollinger Band | 6.55 |
| Percent B (%b) | -0.02 |
| BandWidth | 43.68 |
| MACD Line | -0.62 |
| MACD Signal Line | -0.41 |
| MACD Histogram | -0.2145 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.17 | ||||
| Resistance 3 (R3) | 7.21 | 7.01 | 7.06 | ||
| Resistance 2 (R2) | 7.01 | 6.84 | 7.00 | 7.02 | |
| Resistance 1 (R1) | 6.75 | 6.73 | 6.65 | 6.71 | 6.98 |
| Pivot Point | 6.55 | 6.55 | 6.51 | 6.54 | 6.55 |
| Support 1 (S1) | 6.29 | 6.38 | 6.19 | 6.25 | 5.98 |
| Support 2 (S2) | 6.09 | 6.27 | 6.08 | 5.94 | |
| Support 3 (S3) | 5.83 | 6.09 | 5.91 | ||
| Support 4 (S4) | 5.79 |
